GLOBAL HUMAN MICROBIOME MARKET 2019-2027

Lifesciences | Diagnostic & Biotechnology

GLOBAL HUMAN MICROBIOME MARKET 2019-2027

Market By Products, Applications, Diseases And Geography | Forecast 2019-2027

Request Free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

The detailed analysis by Triton anticipated that the global human microbiome market, in terms of revenue, is expected to display an upward trend and estimated to grow at a CAGR of 21.89% for forecasting period of 2019-2027. The market was assessed to be worth $253.8 million in the year 2018 and is predicted to generate a revenue of approximately $1236.7 million by the year 2027.

Report scope can be customized per your requirements. Request For Customization

The human microbiota includes 10-100 trillion related microbial cells sheltered and possessed by the human body, chiefly bacteria inside the gut. The microbiome of a human includes information about the genes of these cells. Globally, microbiome projects have been initiated to understand the roles played by these symbionts and their influences on human healthiness. Joshua Lederberg coined the term 'Human Microbiome' in 2001. Although bacteria are the most significant part of the human microbiome, the human body also hosts single-celled organisms which are referred as archaea, along with fungi, viruses and other microbes such as viruses that attack the bacteria. Collectively, these are known as the human microbiota. Often, the two terms are used interchangeably. The term “microbiota” can be defined as the bacterial taxa related to humans, and the term ‘microbiome’ can be defined as the collection of these microbes, and it’s genes. 

Also, the term “metagenomics” is often referred to as a classification of total DNA.  However, now it is being applied rapidly to studies related to indicator genes, namely the 16S rRNA gene. However, many new inventions are leading us to query the notions that are important for forming the description of the human microbiome, such as the definition of the Operational Taxonomic Units (OTUs) that make up the microbiota. Other concepts questioned include the stability of an individual's microbiome and whether a person has one form of microbiome or multiple. Microbiome-based treatment and diagnosis methods have been proving to be quite promising, thus conquering the confidence of the investors in the market.

Within this report, the key insights regarding the industry are discussed. Also, Porter’s five force analysis, the regulatory framework, supply chain outlook, key buying outlook, estimate outlook, strategies in product development, parent market outlook and pipeline products are studied for the human microbiome industry. 

Market drivers like precision medicines leading to increased adoption of human microbiomes, the increasing pervasiveness of chronic diseases and emphasis on early disease diagnosis are analyzed. The industry is facing market restraints like lack of technological expertise, barriers in the initial analysis, lack of skilled professionals and stringent government protocols, which are obstructing the industry growth. Key opportunities like increasing R&D investments in the microbiome, high funding for developing new drugs and changing lifestyle in the developing countries can be leveraged by the industry to get towards the projected growth. The sector faces challenges such as lack of awareness at this moment.

To get detailed insights on segments, Download Sample Report

Geographies covered for human microbiome market are:

o    North America: the United States and Canada

o    Europe: United Kingdom, Germany, France, Italy, Spain, Russia and Rest of Europe

o    Asia-Pacific: China, Japan, India, South Korea, ASEAN countries, Australia & New Zealand and Rest of Asia Pacific

o    Latin America: Brazil, Mexico and Rest of Latin America

o    The Middle East and Africa: United Arab Emirates, Turkey, Saudi Arabia, South Africa and Rest of the Middle East and Africa

The human microbiome market report is segmented as follows:

•    By products:

o    Probiotics

o    Foods

o    Prebiotics

o    Medical food

o    Diagnostic devices

o    Drugs 

o    Other products

•    By applications:

o    Drugs

o    Diagnostics

•    By diseases: 

o    Cancer

o    Obesity

o    Ulcerative colitis

o    Crohn’s disease

o    C. Difficle infection

o    Lactose intolerance

o    Dental caries

o    Type 2 diabetes

o    Recurrent bacterial vaginosis and UTI

o    Hyperoxaluria

o    Urea cycle disorder

o    Hepatic Encephalopathy

o    Celiac disease

o    Phenylketonuria

o    Non-alcoholic steatohepatitis


The key players engaged in the human microbiome market are 4D Pharma, Metabiomics, Avidbiotics Inc., Microbiome Therapeutics, Actogenix NV, Metabogen AB, Avidbiotics Corp., Miomics, Enterome SA and Osel Inc. 

The strategic analysis for each of these companies in the human microbiome market is covered in detail. Company market share helps to dive into the information about the key market players in this industry and how much hold they have on the market. With an aim to enhance their market strategies, companies are looking to collaborate with eminent researchers, physicians, and scientists in the human microbiome field.


Major Players in the Market

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1.    GLOBAL HUMAN MICROBIOME MARKET- SUMMARY

2.    INDUSTRY OUTLOOK

2.1. PORTER’S FIVE FORCES OUTLOOK

2.1.1.   THREAT OF NEW ENTRANTS

2.1.2.   THREAT OF SUBSTITUTE PRODUCTS OR SERVICES

2.1.3.   BARGAINING POWER OF BUYER

2.1.4.   BARGAINING POWER OF SUPPLIER

2.1.5.   INTENSITY OF COMPETITIVE RIVALRY

2.2. KEY INSIGHTS

2.3. REGULATORY FRAMEWORK

2.4. SUPPLY CHAIN OUTLOOK

2.5. KEY BUYING OUTLOOK

2.6. ESTIMATE OUTLOOK

2.7. STRATEGIES IN PRODUCT DEVELOPMENT

2.8. PARENT MARKET OUTLOOK

2.9. MARKET SHARE OUTLOOK

2.10.            PIPELINE PRODUCTS

2.11.            MARKET DRIVERS

2.11.1.                PRECISION MEDICINES ARE INCREASING THE ADOPTION OF HUMAN MICROBIOMES

2.11.2.                RISING PERVASIVENESS OF CHRONIC DISEASES

2.11.3.                EMPHASIS ON EARLY DISEASE DIAGNOSIS

2.12.            MARKET RESTRAINTS

2.12.1.                LACK OF TECHNOLOGICAL EXPERTISE

2.12.2.                BARRIERS IN INITIAL ANALYSIS

2.12.3.                LACK OF SKILLED PROFESSIONALS

2.12.4.                STRINGENT GOVERNMENT PROTOCOLS

2.13.            MARKET OPPORTUNITIES

2.13.1.                INCREASING R&D INVESTMENTS IN MICROBIOME

2.13.2.                SWELLING INVESTMENT IN NEW DRUGS

2.13.3.                CHANGING LIFESTYLES IN DEVELOPED COUNTRIES

2.14.            MARKET CHALLENGES

2.14.1.                LACK OF AWARENESS

3.    HUMAN MICROBIOME INDUSTRY OUTLOOK - BY PRODUCTS

3.1. PROBIOTICS

3.2. FOODS

3.3. PREBIOTICS

3.4. MEDICAL FOODS

3.5. DIAGNOSTIC DEVICE

3.6. DRUGS

3.7. OTHER PRODUCTS

4.    HUMAN MICROBIOME INDUSTRY OUTLOOK - BY APPLICATIONS

4.1. DRUGS

4.2. DIAGNOSTICS

5.    HUMAN MICROBIOME INDUSTRY OUTLOOK - BY DISEASES

5.1. CANCER

5.2. OBESITY

5.3. ULCERATIVE COLITIS

5.4. CROHN’S DISEASE

5.5. C. DIFFICLE INFECTION

5.6. LACTOSE INTOLERANCE

5.7. DENTAL CARIES

5.8. TYPE 2 DIABETES

5.9. RECURRENT BACTERIAL VAGINOSIS AND UTI

5.10.            SKIN DISORDERS

5.11.            HYPEROXALURIA

5.12.            UREA CYCLE DISORDER

5.13.            HEPATIC ENCEPHALOPATHY

5.14.            CELIAC DISEASE

5.15.            PHENYLKETONURIA

5.16.            NON-ALCOHOLIC STEATOHEPATITIS

6.    HUMAN MICROBIOME INDUSTRY – REGIONAL OUTLOOK

6.1. NORTH AMERICA

6.1.1.   COUNTRY ANALYSIS

6.1.1.1.      THE UNITED STATES

6.1.1.2.      CANADA

6.2. EUROPE

6.2.1.   COUNTRY ANALYSIS

6.2.1.1.      THE UNITED KINGDOM

6.2.1.2.      FRANCE

6.2.1.3.      GERMANY

6.2.1.4.      ITALY

6.2.1.5.      SPAIN

6.2.1.6.      RUSSIA

6.2.1.7.      REST OF EUROPE

6.3. ASIA PACIFIC

6.3.1.   COUNTRY ANALYSIS

6.3.1.1.      CHINA

6.3.1.2.      INDIA

6.3.1.3.      JAPAN

6.3.1.4.      SOUTH KOREA

6.3.1.5.      AUSTRALIA & NEW ZEALAND

6.3.1.6.      ASEAN COUNTRIES

6.3.1.7.      REST OF APAC

6.4. LATIN AMERICA

6.4.1.   COUNTRY ANALYSIS

6.4.1.1.      BRAZIL

6.4.1.2.      MEXICO

6.4.1.3.      REST OF LATIN AMERICA

6.5. MIDDLE EAST & AFRICA

6.5.1.   COUNTRY ANALYSIS

6.5.1.1.      SAUDI ARABIA

6.5.1.2.      TURKEY

6.5.1.3.      UNITED ARAB EMIRATES

6.5.1.4.      SOUTH AFRICA

6.5.1.5.      REST OF MIDDLE EAST AND AFRICA

7.    COMPETITIVE LANDSCAPE

7.1. 4D PHARMA

7.2. AVIDBIOTICS INC.

7.3. ACTOGENIX N.V. (ACQUIRED BY INTREXON CORPORATION)

7.4. AVIDBIOTICS CORP.

7.5. ENTEROME SA

7.6. METABIOMICS

7.7. MICROBIOME THERAPEUTICS

7.8. METABOGEN AB

7.9. MIOMICS

7.10.            OSEL INC.

7.11.            REBIOTIX

7.12.            RITTER PHARMACEUTICALS, INC.

7.13.            SECOND GENOME

7.14.            SYMBERIX INC.

7.15.            SYMBIOTIX BIOTHERAPIES, INC.

7.16.            VEDANTA BIOSCIENCES, INC. (ACQUIRED BY PURETECH HEALTH PLC)

8.    METHODOLOGY & SCOPE

8.1. RESEARCH SCOPE

8.2. SOURCES OF DATA

RESEARCH METHODOLOGY

List of table

TABLE  1               GLOBAL HUMAN MICROBIOME MARKET BY GEOGRAPHY 2019-2023 ($ MILLION)

TABLE  2               GLOBAL HUMAN MICROBIOME MARKET BY GEOGRAPHY 2023-2027 ($ MILLION)

TABLE  3               INVESTMENTS IN MICROBIOLOGY

TABLE  4               MICROBIOME DRUG DEVELOPMENT APPROACHES

TABLE  5               INCIDENCE OF DIABETES IN THE MAJOR COUNTRIES IN 2016( MILLIONS)

TABLE  6               COMPANIES WORKING TOWARDS DEVELOPING NEW DRUGS

TABLE  7               GLOBAL HUMAN MICROBIOME MARKET BY APPLICATIONS 2019-2023 ($ MILLION)

TABLE  8               GLOBAL HUMAN MICROBIOME MARKET BY APPLICATIONS 2023-2027 ($ MILLION)

TABLE  9               GLOBAL HUMAN MICROBIOME MARKET BY PRODUCTS 2019-2023 ($ MILLION)

TABLE  10             GLOBAL HUMAN MICROBIOME MARKET BY PRODUCTS 2023-2027 ($ MILLION)

TABLE  11             GLOBAL HUMAN MICROBIOME MARKET BY DISEASES 2019-2023 ($ MILLION)

TABLE  12             GLOBAL HUMAN MICROBIOME MARKET BY DISEASES 2023-2027 ($ MILLION)

TABLE  13             MICROBIOTA ASSOCIATED WITH CANCERS

TABLE  14             MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR CANCER

TABLE  15             MICROBIOTA ASSOCIATED WITH OBESITY

TABLE  16             MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR OBESITY

TABLE  17             MICROBIOTA ASSOCIATED WITH TYPE 2 DIABETES

TABLE  18             MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR TYPE 2 DIABETES

TABLE  19             MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR ULCERATIVE COLITIS

TABLE  20             MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR CROHN’S DISEASE

TABLE  21             MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR CLOSTRIDIUM DIFFICLE INFECTION

TABLE  22             MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR CLOSTRIDIUM DIFFICLE INFECTION

TABLE  23             MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR CLOSTRIDIUM DIFFICLE INFECTION

TABLE  24             MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR RECURRENT BACTERIAL VAGINOSIS AND URINARY TRACT INFECTION

TABLE  25             MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR SKIN DISEASES

TABLE  26             MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR SKIN DISEASES

TABLE  27             MICROBIOTA ASSOCIATED WITH CELIAC DISEASE

TABLE  28             MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR CELIAC DISEASE

TABLE  29             MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR UREA CYCLE DISORDER

TABLE  30             MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR NON-ALCOHOLIC STEATOHEPATITIS

TABLE  31             MICROBIOME-BASED DRUGS IN DEVELOPMENT FOR HEPATIC ENCEPHALOPATHY

TABLE  32             GLOBAL HUMAN MICROBIOME MARKET BY GEOGRAPHY 2019-2023 ($ MILLION)

TABLE  33             GLOBAL HUMAN MICROBIOME MARKET BY GEOGRAPHY 2023-2027 ($ MILLION)

TABLE  34             NORTH AMERICA HUMAN MICROBIOME MARKET 2019-2023 ($ MILLION)

TABLE  35             NORTH AMERICA HUMAN MICROBIOME MARKET 2023-2027 ($ MILLION)

TABLE  36             COLLECTIVE PROGRAMS BY CIHR'S ON HUMAN MICROBIOME IN 2017

TABLE  37             EUROPE HUMAN MICROBIOME MARKET 2019-2023 ($ MILLION)

TABLE  38             EUROPE HUMAN MICROBIOME MARKET 2012-2026 ($ MILLION)

TABLE  39             ASIA PACIFIC HUMAN MICROBIOME MARKET 2019-2023 ($ MILLION)

TABLE  40             ASIA PACIFIC HUMAN MICROBIOME MARKET 2023-2027 ($ MILLION)

TABLE  41             LATIN AMERICA HUMAN MICROBIOME MARKET 2019-2023 ($ MILLION)

TABLE  42             LATIN AMERICA HUMAN MICROBIOME MARKET 2023-2027 ($ MILLION)

TABLE  43             MIDDLE EAST AND AFRICA HUMAN MICROBIOME MARKET 2019-2023 ($ MILLION)

TABLE  44             MIDDLE EAST AND AFRICA HUMAN MICROBIOME MARKET 2023-2027 ($ MILLION)

List of Figures

FIGURE 1      GLOBAL HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 2      HEALTHCARE EXPENDITURE IN THE U.S. 2015-2025 (% OF GDP)

FIGURE 3      RESEARCH AND DEVELOPMENT SPENDING IN THE LIFE SCIENCE 2014-2016 ($ BILLION)

FIGURE 4      ESTIMATED NUMBER OF PEOPLE WITH CHRONIC CONDITIONS IN UNITED STATES

FIGURE 5      GLOBAL HUMAN MICROBIOME MARKET IN DRUGS 2019-2027 ($ MILLION)

FIGURE 6      GLOBAL HUMAN MICROBIOME MARKET IN DIAGNOSTIC DEVICE 2019-2027 ($ MILLION)

FIGURE 7      GLOBAL HUMAN MICROBIOME MARKET IN PROBIOTICS 2019-2027 ($ MILLION)

FIGURE 8      GLOBAL HUMAN MICROBIOME MARKET IN FOODS 2019-2027 ($ MILLION)

FIGURE 9      GLOBAL HUMAN MICROBIOME MARKET IN PREBIOTICS 2019-2027 ($ MILLION)

FIGURE 10   GLOBAL HUMAN MICROBIOME MARKET IN MEDICAL FOODS 2019-2027 ($ MILLION)

FIGURE 11   GLOBAL HUMAN MICROBIOME MARKET IN DIAGNOSTIC DEVICE 2019-2027 ($ MILLION)

FIGURE 12   GLOBAL HUMAN MICROBIOME MARKET IN DRUGS 2019-2027 ($ MILLION)

FIGURE 13   GLOBAL HUMAN MICROBIOME MARKET IN OTHER PRODUCTS 2019-2027 ($ MILLION)

FIGURE 14   GLOBAL HUMAN MICROBIOME MARKET IN CANCER 2019-2027 ($ MILLION)

FIGURE 15   GLOBAL HUMAN MICROBIOME MARKET IN OBESITY 2019-2027 ($ MILLION)

FIGURE 16   GLOBAL HUMAN MICROBIOME MARKET IN TYPE 2 DIABETES 2019-2027 ($ MILLION)

FIGURE 17   GLOBAL HUMAN MICROBIOME MARKET IN ULCERATIVE COLITIS 2019-2027 ($ MILLION)

FIGURE 18   GLOBAL HUMAN MICROBIOME MARKET IN CROHN’S DISEASE 2019-2027 ($ MILLION)

FIGURE 19   GLOBAL HUMAN MICROBIOME MARKET IN C. DIFFICLE INFECTION 2019-2027 ($ MILLION)

FIGURE 20   GLOBAL HUMAN MICROBIOME MARKET IN LACTOSE INTOLERANCE 2019-2027 ($ MILLION)

FIGURE 21   GLOBAL HUMAN MICROBIOME MARKET IN DENTAL CARIES 2019-2027 ($ MILLION)

FIGURE 22   GLOBAL HUMAN MICROBIOME MARKET IN RECURRENT BACTERIAL VAGINOSIS AND UTI 2019-2027 ($ MILLION)

FIGURE 23   GLOBAL HUMAN MICROBIOME MARKET IN SKIN DISORDERS 2019-2027 ($ MILLION)

FIGURE 24   MICROBES INVOLVED IN HEALTHY FACIAL SKIN (PERCENT MICROBES)

FIGURE 25   GLOBAL HUMAN MICROBIOME MARKET IN HYPEROXALURIA 2019-2027 ($ MILLION)

FIGURE 26   GLOBAL HUMAN MICROBIOME MARKET IN CELIAC DISEASE 2019-2027 ($ MILLION)

FIGURE 27   GLOBAL HUMAN MICROBIOME MARKET IN UREA CYCLE DISORDER 2019-2027 ($ MILLION)

FIGURE 28   GLOBAL HUMAN MICROBIOME MARKET IN PHENYLKETONURIA 2019-2027 ($ MILLION)

FIGURE 29   GLOBAL HUMAN MICROBIOME MARKET IN NON-ALCOHOLIC STEATOHEPATITIS 2019-2027 ($ MILLION)

FIGURE 30   GLOBAL HUMAN MICROBIOME MARKET IN HEPATIC ENCEPHALOPATHY 2019-2027 ($ MILLION)

FIGURE 31   NORTH AMERICA HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 32   THE U.S. HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 33   CANADA HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 34   EUROPE HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 35   THE UNITED KINGDOM HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 36   FRANCE HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 37   GERMANY HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 38   ITALY HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 39   SPAIN HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 40   RUSSIA HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 41   REST OF EUROPE HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 42   ASIA PACIFIC HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 43   CHINA HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 44   INDIA HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 45   JAPAN HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 46   SOUTH KOREA HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 47   AUSTRALIA & NEW ZEALAND HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 48   ASEAN COUNTRIES HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 49   REST OF APAC HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 50   REST OF WORLD HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 51   LATIN AMERICA HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 52   BRAZIL HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 53   MEXICO HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 54   REST OF LATIN AMERICA HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 55   MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 56   SAUDI ARABIA HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 57   TURKEY HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 58   UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 59   SOUTH AFRICA HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 60   REST OF MIDDLE EAST AND AFRICA HUMAN MICROBIOME MARKET 2019-2027 ($ MILLION)

FIGURE 61   MARKET SHARE ANALYSIS OF GLOBAL HUMAN MICROBIOME MARKET 2018 (%)

Major Players in the Market

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$2,750.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$4,000.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

;